Indication*

Type 2 DM as initial therapy to improve glycemic control when diet & exercise alone do not provide adequate glycemic control. Type 2 DM as adjunct to diet & exercise to improve glycemic control in patients who can not be controlled with metformin or sitagliptin alone or in patients already being treated with combination of sitagliptin & metformin. As part of triple combination therapy with a sulfonylurea or with a PPARY agonist (ie, thiazolidinediones) as an adjunct to diet & exercise in patients with type 2 DM inadequately controlled with any 2 of 3 agents: Metformin, sitagliptin or a sulfonylurea alone or a PPARY agonist alone. Type 2 DM as an adjunct to diet & exercise to improve glycemic control in combination with insulin; sitagliptin & metformin.

Directions for Use*

Individualized dosing. Initial therapy: Starting dose 50 mg/500 mg bid. May be titrated with sitagliptin 50mg + metformin 1,000 mg bid. Patient inadequately controlled on metformin monotherapy Sitagliptin 50 mg bid + metformin already taken. Patient inadequately controlled on sitagliptin monotherapy 50 mg/ 500 mg tab bid. May be titrated up to 50 mg/1,000 mg tab bid. Patient inadequately controlled on dual combination therapy with any 2 of the following 3 antihyperglycemic agents: Sitagliptin, metformin or a PPARY agonist (ie, thiazolidinediones) Usual starting dose: 50 mg bid (100 mg total daily dose). In determining the starting dose of the metformin component, the patient's level of glycemic control & current dose (if any) of metformin should be considered.

Administration*

Should be taken with food.

*written indications, directions, and administration are updated as of March 05, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details